The epidermal growth factor receptor (EGFR) belongs to the HER/erbB tyrosine kinase (RTK) family, serving as a crucial target for cancer treatment. Anti-EGFR drugs, used primary treatment patients with advanced EGFR gene mutations such T790M, C797S, and L858R, have shown greater efficacy safety compared standard chemotherapy. This study aimed screen alkaloid compounds anticancer activity, extra...